Vegelaled palches al íhe lailing showed similar characlerislics of pH, salís and organic maller conlenl, and showed a lolal copper concenlralion lower íhan íhe conlenl found ai íhe non-vegelaled patches. Nine plant species present at the site were screened for copper accumulation and...
Idelalisib recommended by NICE for CLLThe article reports that Great Britain's National Institute for Health and Care Excellence (NICE) has issued a draft in which it assured effective use of idelalisib drug in the treatment of patients suffering from chronic lymphocytic leukaemia (CLL)....
As a result of this new data, Zent, an international expert in CLL, recommends that all clinical teams who care for CLL patients should actively monitor for melanoma as a part of routine care. The goal is to catch the skin cancer early and manage it with the newest targeted therapies. "...
Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine. Chemotherapy and radiation therapy should be the first line of treatment f...
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed Campath-1H is an active drug in T-PLL patients for whom first-line therapy has failed. It has a favorable risk/benefit ratio and should be ... Keating, M. J,B...
NKX-019 is under development for the treatment of B-cell malignancies including B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), follicular lymphoma, marginal zone b-cell lymphoma, mantle...
Patients with CLL are at a higher risk of infections, partly due to disease and partly due to the immune dysfunction induced by treatment, such as purine analogous-based chemoimmunotherapy, which leads to lymphocyte depletion. Infections are a leading cause of complications and death in CLL ...
This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for ... S Lentzsch,A O'Sullivan,RC Kennedy,... - 《Blood》 被引量: 177发表: 2012年 Weekly administration of bendamustine: a phase I study in...
Conservative treatment recommended for CLLdoi:10.2165/00128413-199911930-00032SpringerInpharma Weekly